Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according ...

Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...

Vaccines and monoclonal antibodies are reducing RSV hospitalizations, but high costs and limited access in low-income ...

The death comes as multiple infectious diseases are surging throughout the US, including the 10th wave of the COVID-19 ...

Respiratory illnesses have ticked up across Illinois in recent weeks. The Illinois Department of Public Health reports the ...

Sanofi bought into the nirsevimab programme in 2017, paying $645 million for marketing rights to the antibody, with AZ retaining the responsibility for developing and manufacturing it.

It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV ...

Queenslanders have been urged to overcome ‘vaccine fatigue’ and take up an offer of free vaccinations amid predictions of a ...

Ontario is funding Beyfortus, an injectable ready-made antibody that fights RSV for up to six months for all infants under 12 months of age. Babies born at Sault Area Hospital during the RSV season ...

The Illinois Department of Public Health (IDPH) announced that in line with the national trend, the state’s overall respiratory illness level has ticked up from Moderate to High, driven by ...